The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue British Journal of Cancer Année : 2018

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma

Julie Creuzet
  • Fonction : Auteur
Abir Khalil-Mgharbel
  • Fonction : Auteur
Alban Deroux
  • Fonction : Auteur
  • PersonId : 964950
Jean-Louis Quesada
Odile Filhol
Céline Ferlay-Segura
  • Fonction : Auteur
Delphine Borchiellini
  • Fonction : Auteur

Résumé

Vascular endothelial (VE)-cadherin is an endothelial cell-specific protein responsible for endothelium integrity. Its adhesive properties are regulated by post-translational processing, such as tyrosine phosphorylation at site Y685 in its cytoplasmic domain, and cleavage of its extracellular domain (sVE). In hormone-refractory metastatic breast cancer, we recently demonstrated that sVE levels correlate to poor survival. In the present study, we determine whether kidney cancer therapies had an effect on VE-cadherin structural modifications and their clinical interest to monitor patient outcome.

Dates et versions

hal-02005080 , version 1 (03-02-2019)

Identifiants

Citer

Helena Polena, Julie Creuzet, Maeva Dufies, Adama Sidibé, Abir Khalil-Mgharbel, et al.. The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma. British Journal of Cancer, 2018, 118 (9), pp.1179-1188. ⟨10.1038/s41416-018-0054-5⟩. ⟨hal-02005080⟩
122 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More